Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 13/20 | 0.49 |
| ▸ | STAMBP | O95630 | 12/20 | 0.49 |
| ▸ | COPS5 | Q92905 | 10/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539653 | 0.89 | PSMD14 (0.52) | PSMD14STAMBPCOPS5GAAHPGDS | |
| SCHEMBL18539660 | 0.87 | STAMBP (0.57) | PSMD14STAMBPCOPS5 | |
| SCHEMBL18541937 | 0.84 | STAMBP (0.54) | PSMD14STAMBPCOPS5 | |
| SCHEMBL18539642 | 0.79 | PSMD14 (0.76) | PSMD14STAMBPCOPS5HPGDS | |
| SCHEMBL29563919 | 0.79 | PSMD14 (0.76) | PSMD14STAMBPCOPS5HPGDS | |
| SCHEMBL18539656 | 0.77 | MAPK1 (0.59) | PSMD14STAMBPCOPS5LMNA | |
| SCHEMBL18539654 | 0.76 | STAMBP (0.51) | PSMD14STAMBPCOPS5NPC1 | |
| SCHEMBL18539663 | 0.76 | STAMBP (0.60) | PSMD14STAMBPCOPS5 | |
| SCHEMBL18539643 | 0.76 | PSMD14 (0.76) | PSMD14STAMBPCOPS5LMNANPC1 | |
| SCHEMBL18539641 | 0.74 | PSMD14 (0.76) | PSMD14STAMBPCOPS5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019238817-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING RPN11 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| US-10005735-B2 | Inhibitors of RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005735-B2 | Inhibitors of RPN11 | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170050931-A1 | INHIBITORS OF RPN11 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-23 | — | — | US | disclosed |
| US-20170050931-A1 | INHIBITORS OF RPN11 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050931-A1 | INHIBITORS OF RPN11 | POLR2A, RPP30, RPIA | PSMD14 418/4885STAMBP 3835/4885COPS5 700/4885 |
| US-10005735-B2 | Inhibitors of RPN11 | POLR2A, RPP30, RPIA | PSMD14 418/4885STAMBP 3835/4885COPS5 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.